DowDuPont Inc. , which was formed through the merger of Dow Chemical and DuPont, engages in agriculture, materials science, and specialty products businesses globally.
Earnings
DowDuPont raked in adjusted earnings of $1.12 per share for the first quarter that topped the Zacks Consensus Estimate of $1.08.
Revenues
DowDuPont logged net sales of $21,510 million. It surpassed the Zacks Consensus Estimate of $21,320 million.
Estimate Trend
Investors should note that the earnings estimate for DowDuPont for the first quarter have been stable over the past month.
Key Stats/Developments to Note
The company realized cost synergy savings of more than $300 million in the first quarter and is on track to deliver a 75% run-rate against its $3.3 billion cost synergy target by the end of the third-quarter 2018. It also returned around $2 billion to shareholders in the first quarter through dividends and share repurchases.
DowDuPont expects net sales in the second quarter to increase more than 10% and operating EBITDA to rise more than 20% on a year-over-year basis.
DowDuPont will remain committed to achieve the cost synergy target, execute its growth projects and deliver new products from its innovation pipeline. The company also expects the spin-off of its Materials Science business to complete by the end of first-quarter 2019 followed by the separation of Agriculture and Specialty Products businesses by Jun 1, 2019.
Zacks Rank
DowDuPont currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Market Reaction
DowDuPont’s shares were inactive in pre-market trading. It would be interesting to see how the market reacts to the results during the trading session today.
Check back later for our full write up on DowDuPont’s earnings report!
5 Medical Stocks to Buy Now
Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia, AIDS, muscular dystrophy, hemophilia, and other conditions.
New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline. Early investors could realize exceptional profits.
Click here to see the 5 stocks >>
Image: Bigstock
DowDuPont (DWDP) Q1 Earnings & Revenues Beat Estimates
DowDuPont Inc. , which was formed through the merger of Dow Chemical and DuPont, engages in agriculture, materials science, and specialty products businesses globally.
Earnings
DowDuPont raked in adjusted earnings of $1.12 per share for the first quarter that topped the Zacks Consensus Estimate of $1.08.
Revenues
DowDuPont logged net sales of $21,510 million. It surpassed the Zacks Consensus Estimate of $21,320 million.
Estimate Trend
Investors should note that the earnings estimate for DowDuPont for the first quarter have been stable over the past month.
Key Stats/Developments to Note
The company realized cost synergy savings of more than $300 million in the first quarter and is on track to deliver a 75% run-rate against its $3.3 billion cost synergy target by the end of the third-quarter 2018. It also returned around $2 billion to shareholders in the first quarter through dividends and share repurchases.
DowDuPont expects net sales in the second quarter to increase more than 10% and operating EBITDA to rise more than 20% on a year-over-year basis.
DowDuPont will remain committed to achieve the cost synergy target, execute its growth projects and deliver new products from its innovation pipeline. The company also expects the spin-off of its Materials Science business to complete by the end of first-quarter 2019 followed by the separation of Agriculture and Specialty Products businesses by Jun 1, 2019.
Zacks Rank
DowDuPont currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Market Reaction
DowDuPont’s shares were inactive in pre-market trading. It would be interesting to see how the market reacts to the results during the trading session today.
Check back later for our full write up on DowDuPont’s earnings report!
5 Medical Stocks to Buy Now
Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia, AIDS, muscular dystrophy, hemophilia, and other conditions.
New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline. Early investors could realize exceptional profits.
Click here to see the 5 stocks >>